UC-1V150 is a distinct TLR7 agonist, which activates cellular immune responses and exhibits anti-tumor effects. It also serves as a precursor for the synthesis of ISAC molecules, known as immune-stimulating antibody conjugates [1] [2].

UC-1V150, at concentrations ranging from 0.01 to 10 μM over a 24-hour period, effectively promotes the secretion of IL-6 and IL-2 cytokines in bone-marrow-derived macrophages [1]. Additionally, when administered at 1 μg/mL for 48 hours, it enhances the expression of FcγRIIA and FcγRIII and induces a roughly 1.5-fold enhancement in the phagocytosis index of target cells in human monocyte-derived macrophages (hMDM) [2].

UC-1V150, administered via a single intravenous injection at concentrations ranging from 0.38-38 nM for 2 hours, effectively triggers the release of serum cytokines in female C57BL/6 mice aged 5-6 weeks. This administration resulted in serum interleukin-6 (IL-6) levels reaching approximately 0.1 ng/mL and interleukin-2 (IL-2) levels reaching approximately 1.5 ng/mL at the 38 nM concentration.